The global human insulin market size reached US$ 45.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 68.0 Billion by 2028, exhibiting a growth rate (CAGR) of 6.48% during 2023-2028. More Info:- https://www.imarcgroup.com/human-insulin-market

1. Copyright © IMARC Service Pvt Ltd. All Rights Reserved
Global Human Insulin Market
Research and Forecast
Report 2023-2028
Author: Elena Anderson,
Marketing Manager |
IMARC Group
© 2019 IMARC All Rights Reserved

2. Report Description
About IMARC Group
The International Market Analysis Research and Consulting Group is a leading adviser on
management strategy and market research worldwide. We partner with clients in all sectors
and regions to identify their highest-value opportunities, address their most critical
challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
chemicals, food and beverage, travel and tourism, nanotechnology and novel processing
methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our
clients achieve unmatchable competitive advantage, build more proficient organizations, and
secure lasting results.

3. Report Description
Report Description and Highlights
Global Human Insulin Market Research Report:
The latest report by IMARC, titled “Human Insulin Market: Global Industry Trends, Share, Size,
Growth, Opportunity and Forecast 2023-2028” finds that the global human insulin market size
reached US$ 45.0 Billion in 2022.
Human insulin (HI), also known as regular insulin, refers to short-acting insulin synthesized in
laboratories. It mimics the function of insulin naturally produced by the human body and is generally
injected subcutaneously multiple times a day. It is bio-engineered by growing insulin proteins within E-
coli bacteria (Escherichia coli) cells.
It is widely used to regulate blood sugar levels in patients with type I and II diabetes and promote
glucose uptake from the blood into internal organs and tissues, such as liver and fat cells. It also inhibits
hepatic glucose production and enhances the protein synthesis of the body.
Request Free Sample Report: https://www.imarcgroup.com/human-insulin-market/requestsample

4. Report Description
Report Description and Highlights
Global Human Insulin Market Trends:
The surging incidences of diabetes due to the aging population, sedentary lifestyles, and unhealthy dietary habits
represent the primary factor driving the market growth. Additionally, there has been growing consumer awareness
regarding the complications of prolonged diabetes, such as cataracts, heart attacks, and kidney failure. In line with
this, the escalating demand for biosimilar drugs on account of their high efficiency and cost-effectiveness has
catalyzed market growth. Furthermore, several key players are extensively investing in research and development
(R&D) activities to develop oral insulin variants that provide a safe, effective, and convenient method of delivering
insulin therapy. Apart from this, the introduction of pen devices and safety pen needles that cause minimal
discomfort and reduce the risks of injuries, infections, and bloodborne pathogen transmission has accelerated the
product adoption rate.
Moreover, the implementation of stringent government policies against needle stick injuries and the shifting
consumer preferences toward minimally invasive (MI) devices have encouraged the usage of pen devices and safety
pen needles for HI administration. Other factors, including the expanding obese population, improving healthcare
infrastructure, increasing consumer health consciousness, recent advancements in the biotechnology field, and
product innovations, are also providing a positive thrust to the market growth. Looking forward, the market value is
expected to reach US$ 68.0 Billion by 2028, exhibiting a CAGR of 6.48% during the forecast period (2023-2028).
Looking forward, the market value is projected to reach a strong growth during the forecast period
(2023-2028).

5. Report Description
Report Description and Highlights
Market Summary:
Breakup by Product Type:
•Drugs
o Human Insulin Analogs and Biosimilars
• Rapid Acting
• Long Acting
• Premixed
o Human Insulin Biologics
• Short Acting
• Intermediate Acting
• Premixed
•Delivery Devices
o Pens
• Reusable Pens
• Disposable Pens
o Pen Needles
• Standard Pen Needles
• Safety Pen Needles

6. Report Description
Report Description and Highlights
•Syringes
•Others
Breakup by Distribution Channel:
•Retail Pharmacies
•Hospital Pharmacies
•Online Retail Stores
•Others
Breakup by Disease Type:
•Type I Diabetes
•Type II Diabetes
Breakup by Region:
• North America
• United States
• Canada
• Asia-Pacific
• China

7. • Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
Report Description
Report Description and Highlights

8. Competitive Landscape with Key Players:
• B. Braun Melsungen AG
• Becton
• Dickinson and Company (BD)
• Biocon
• Eli Lilly and Company
• Gulf Pharmaceutical Industries (Julphar)
• Novo Nordisk A/S
• Pfizer Inc.
• Groupe Sanofi
• SEDICO Co. Wockhardt Limited
• Ypsomed AG
View Full Report with TOC & List of Figure: https://www.imarcgroup.com/human-insulin-market
Report Description
Report Description and Highlights

9. A partial List of our Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
Partial List of Clients

10. A partial List of our Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
Partial List of Clients

11. Report Description
Report Description and Highlights
© 2019 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of
International Market Analysis Research and Consulting (IMARC). No part of this publication may be
reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be
used in any form or by and means graphic electronic or mechanical, including photocopying, recording,
taping or by information storage or retrieval, or by any other form, without the express consent of
International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been
based on information and sources believed to be accurate and reliable at the time of publishing.
International Market Analysis Research and Consulting makes no representation of warranty of any kind as to
the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any
loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market
Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of
their respective companies.

12. FOR MORE DETAILS
Visit us at :
Stay With Us:
TELEPHONE: +1-631-791-1145
E-MAIL: sales@imarcgroup.com
https://www.imarcgroup.com
Contact Us